CYP2D6 and Tamoxifen: Awaiting the Denouement Reply

被引：0
作者：
Rae, James M. [1 ]
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 34期
关键词：
PHARMACOGENETICS; METABOLITE;
D O I：
10.1200/JCO.2011.39.0971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4590 / 4591
页数：3
相关论文
共 50 条
[41]   Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment [J].
Stingl, Julia Carolin ;
Parmar, Sumit ;
Huber-Wechselberger, Ariana ;
Kainz, Alexander ;
Renner, Wilfried ;
Seeringer, Angela ;
Brockmoeller, Juergen ;
Langsenlehner, Uwe ;
Krippl, Peter ;
Haschke-Becher, Elisabeth .
CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (11) :2535-2542
[42]   Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen [J].
Schroth, Werner ;
Winter, Stefan ;
Muerdter, Thomas ;
Schaeffeler, Elke ;
Eccles, Diana ;
Eccles, Bryony ;
Chowbay, Balram ;
Khor, Chiea C. ;
Tfayli, Arafat ;
Zgheib, Nathalie K. ;
Eichelbaum, Michel ;
Schwab, Matthias ;
Brauch, Hiltrud .
FRONTIERS IN PHARMACOLOGY, 2017, 8
[43]   National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China [J].
Lin, Guigao ;
Zhang, Kuo ;
Yi, Lang ;
Han, Yanxi ;
Xie, Jiehong ;
Li, Jinming .
PLOS ONE, 2016, 11 (09)
[44]   CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients [J].
Ahmed, Jemal Hussien ;
Makonnen, Eyasu ;
Fotoohi, Alan ;
Aseffa, Abraham ;
Howe, Rawleigh ;
Aklillu, Eleni .
CANCERS, 2019, 11 (09)
[45]   Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment [J].
Park, Hyung Seok ;
Choi, Ji-Yeob ;
Lee, Mi-Jeong ;
Park, Seho ;
Yeo, Chang-Woo ;
Lee, Sang Seop ;
Shin, Jae-Gook ;
Park, Byeong-Woo .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (08) :1007-1013
[46]   The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva [J].
Jin, Ye ;
Zhang, Shuquan ;
Hu, Pei ;
Zheng, Xin ;
Guan, Xiaoduo ;
Chen, Rui ;
Zhang, Shuyang .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[47]   GenoChip CYP2D6 macroarray as a method to genotype for CYP2D6 variants: results of a validation study in a Caucasian population [J].
Bank, Paul C. D. ;
Swen, Jesse J. ;
Guchelaar, Henk-Jan ;
van der Straaten, Tahar .
PHARMACOGENOMICS, 2015, 16 (07) :681-687
[48]   Highlights from the latest articles in CYP2D6 activity and breast cancer outcomes during treatment with tamoxifen [J].
Dorado, Pedro ;
Penas-Lledo, Eva ;
LLerena, Adrian .
PHARMACOGENOMICS, 2013, 14 (06) :603-604
[49]   Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy [J].
Alastair M. Thompson ;
Andrea Johnson ;
Philip Quinlan ;
Grantland Hillman ;
Marcel Fontecha ;
Susan E. Bray ;
Colin A. Purdie ;
Lee B. Jordan ;
Roberta Ferraldeschi ;
Ayshe Latif ;
Kirsten D. Hadfield ;
Robert B. Clarke ;
Linda Ashcroft ;
D. Gareth Evans ;
Anthony Howell ;
Michele Nikoloff ;
Jeffrey Lawrence ;
William G. Newman .
Breast Cancer Research and Treatment, 2011, 125 :279-287
[50]   A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen [J].
Harriet Johansson ;
Sara Gandini ;
Davide Serrano ;
Jennifer Gjerde ;
Monia Lattanzi ;
Debora Macis ;
Aliana Guerrieri-Gonzaga ;
Valentina Aristarco ;
Gunnar Mellgren ;
Ernst Lien ;
Andrea DeCensi ;
Bernardo Bonanni .
Breast Cancer Research and Treatment, 2016, 159 :97-108
12345